The earnings call reflected a well-managed quarter with robust strategic initiatives and strong cost management, despite facing significant revenue declines and challenges in the U.S. academic market. The company's strong cash position and strategic product expansions provide a positive outlook, though the impact of tariffs and revenue declines remain concerns.

Company Guidance

During the Standard BioTools first quarter 2025 earnings call, the company reiterated its full-year revenue guidance of $165 million to $175 million, despite a 10% year-over-year decline in Q1 revenue to $40.8 million. The decline was primarily due to lower consumables and services revenue, with consumables down 16% and services down 16% year-over-year. Instrument sales, however, grew by 24%, driven by the Hyperion XTi system. The company reported non-GAAP gross margins of 53.2%, impacted by lower volumes and product mix, and a non-GAAP operating loss improvement of 45% year-over-year. Adjusted EBITDA loss improved 29% to $16.9 million, and cash burn was reduced by 33%. The company emphasized its strategic focus on proteomics and highlighted new product launches, including the CyTOF-XT Pro and SomaScan Select Asset, as key drivers for future growth.

Strategic Product Launches and Expansions

Standard BioTools announced a new SomaScan offering and expanded its reach with the NGS-based Illumina partner solution, enhancing translational and clinical research capabilities.

Strength in Instrument Sales

Instruments saw a double-digit year-over-year growth, driven by demand for Hyperion XTi spatial imaging systems.

Cost Management and Operational Improvements

Non-GAAP operating expenses decreased by 22% year-over-year, operating loss improved by 45%, and adjusted EBITDA improved by 29%.

Healthy Cash Position

Standard BioTools ended the quarter with $261 million in cash and no material debt, emphasizing a strong balance sheet.

Positive Traction with Pharma and International Markets

Biopharma engagement and international markets remained resilient, contributing positively to overall performance.

Standard BioTools (LAB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LAB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.04 / -	-0.07	―	―	―
Aug 11, 2025	2025 (Q2)	-0.07 / -0.05	-0.12	58.33% (+0.07)	―	―
May 06, 2025	2025 (Q1)	-0.06 / -0.07	-0.27	74.07% (+0.20)
Feb 26, 2025	2024 (Q4)	-0.06 / -0.09	-0.25	64.00% (+0.16)
Oct 30, 2024	2024 (Q3)	-0.09 / -0.07	-0.27	74.07% (+0.20)
Jul 31, 2024	2024 (Q2)	-0.08 / -0.12	-0.22	45.45% (+0.10)
May 08, 2024	2024 (Q1)	-0.11 / -0.27	-0.21	-28.57% (-0.06)
Feb 28, 2024	2023 (Q4)	-0.24 / -0.25	-0.26	3.85% (+0.01)
Nov 07, 2023	2023 (Q3)	-0.23 / -0.27	-0.37	27.03% (+0.10)
Aug 08, 2023	2023 (Q2)	-0.21 / -0.22	-0.82	73.17% (+0.60)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LAB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 11, 2025	$1.28	$1.31	+2.34%
May 06, 2025	$1.06	$1.02	-3.77%
Feb 26, 2025	$1.17	$1.04	-11.11%
Oct 30, 2024	$1.88	$1.96	+4.26%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Standard BioTools (LAB) report earnings?

Standard BioTools (LAB) is schdueled to report earning on Nov 11, 2025, After Close (Confirmed).

What is Standard BioTools (LAB) earnings time?

Standard BioTools (LAB) earnings time is at Nov 11, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LAB EPS forecast?

LAB EPS forecast for the fiscal quarter 2025 (Q3) is -0.04.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing